BACKGROUND: This meta-analysis evaluated the efficacy of PD-L1/PD-1 immunotherapy compared with chemotherapy in IIIB or IV or recurrent squamous non-small cell lung cancer (NSCLC) patients. METHODS: We performed a literature search on the PubMed, EMBASE, Web of Science, and Cochrane databases, in addition to the abstracts from major conference proceedings of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the World Conference on Lung Cancer (WCLC) from 2004 to May 2019. Randomized controlled trials that compared PD-L1/PD-1 immunotherapy with chemotherapy in IIIB or IV or recurrent squamous NSCLC were included. The endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), 1-y OS rate, and 1-y PFS rate. RESULTS: A total of 3,213 IIIB or IV or recurrent squamous NSCLC patients from 12 trials of high quality were included in this meta-analysis, among whom 1,677 were in the PD-L1/PD-1 immunotherapy group and 1,536 were in the chemotherapy group. The results indicated that compared with chemotherapy, immunotherapy significantly prolonged OS (HR =0.75; 95% CI, 0.68-0.83; P<0.001) and PFS (HR =0.66; 95% CI, 0.60-0.73; P<0.001) in patients with advanced squamous NSCLC. The pooled model showed that ORR, DCR, and 1-y PFS rate were also significantly higher with immunotherapy compared with chemotherapy (ORR: RR =1.43; 95% CI, 1.11-1.83; P=0.005; DCR: RR =1.14; 95% CI, 1.05-1.24; P=0.003; 1-y PFS rate: RR =2.30; 95% CI, 1.69-3.13; P<0.001). The 1-y OS rate tended to be higher in the immunotherapy group, but there was no significant difference compared with chemotherapy (RR =1.28; 95% CI, 0.95-1.72; P=0.104). CONCLUSIONS: Our study proves that PD-L1/PD-1 immunotherapy can significantly improve OS, PFS, ORR, DCR, and 1-y PFS of metastatic squamous NSCLC patients compared with chemotherapy. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: This meta-analysis evaluated the efficacy of PD-L1/PD-1 immunotherapy compared with chemotherapy in IIIB or IV or recurrent squamous non-small cell lung cancer (NSCLC) patients. METHODS: We performed a literature search on the PubMed, EMBASE, Web of Science, and Cochrane databases, in addition to the abstracts from major conference proceedings of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the World Conference on Lung Cancer (WCLC) from 2004 to May 2019. Randomized controlled trials that compared PD-L1/PD-1 immunotherapy with chemotherapy in IIIB or IV or recurrent squamous NSCLC were included. The endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), 1-y OS rate, and 1-y PFS rate. RESULTS: A total of 3,213 IIIB or IV or recurrent squamous NSCLC patients from 12 trials of high quality were included in this meta-analysis, among whom 1,677 were in the PD-L1/PD-1 immunotherapy group and 1,536 were in the chemotherapy group. The results indicated that compared with chemotherapy, immunotherapy significantly prolonged OS (HR =0.75; 95% CI, 0.68-0.83; P<0.001) and PFS (HR =0.66; 95% CI, 0.60-0.73; P<0.001) in patients with advanced squamous NSCLC. The pooled model showed that ORR, DCR, and 1-y PFS rate were also significantly higher with immunotherapy compared with chemotherapy (ORR: RR =1.43; 95% CI, 1.11-1.83; P=0.005; DCR: RR =1.14; 95% CI, 1.05-1.24; P=0.003; 1-y PFS rate: RR =2.30; 95% CI, 1.69-3.13; P<0.001). The 1-y OS rate tended to be higher in the immunotherapy group, but there was no significant difference compared with chemotherapy (RR =1.28; 95% CI, 0.95-1.72; P=0.104). CONCLUSIONS: Our study proves that PD-L1/PD-1 immunotherapy can significantly improve OS, PFS, ORR, DCR, and 1-y PFS of metastatic squamous NSCLC patients compared with chemotherapy. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Y Ohe; Y Ohashi; K Kubota; T Tamura; K Nakagawa; S Negoro; Y Nishiwaki; N Saijo; Y Ariyoshi; M Fukuoka Journal: Ann Oncol Date: 2006-11-01 Impact factor: 32.976
Authors: Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: O Akbari; P Stock; A K Singh; V Lombardi; W-L Lee; G J Freeman; A H Sharpe; D T Umetsu; R H Dekruyff Journal: Mucosal Immunol Date: 2009-09-09 Impact factor: 7.313
Authors: Fabrice Barlesi; Johan Vansteenkiste; David Spigel; Hidenobu Ishii; Marina Garassino; Filippo de Marinis; Mustafa Özgüroğlu; Aleksandra Szczesna; Andreas Polychronis; Ruchan Uslu; Maciej Krzakowski; Jong-Seok Lee; Luana Calabrò; Osvaldo Arén Frontera; Barbara Ellers-Lenz; Marcis Bajars; Mary Ruisi; Keunchil Park Journal: Lancet Oncol Date: 2018-09-24 Impact factor: 41.316